Additional file 1 of A continuously efficient O2-supplying strategy for long-term modulation of hypoxic tumor microenvironment to enhance long-acting radionuclides internal therapy
Creators: name: Li, Jingchao
name: Wang, Tingting
name: Shi, Yuanfei
name: Ye, Zichen
name: Zhang, Xun
name: Ming, Jiang
name: Zhang, Yafei
name: Hu, Xinyan
name: Li, Yun
name: Zhang, Dongsheng
name: Xu, Qianhe
name: Yang, Jun
name: Chen, Xiaolan
name: Liu, Nian
name: Su, Xinhui
Publisher: name: figshare
Year: 2024
Subjects: subject: Medicine
subject: Pharmacology
subject: Biotechnology
subject: Chemical Sciences not elsewhere classified
subject: Sociology
subject: FOS: Sociology
subject: Cancer

description: Additonal file 1: Figure S1: TEM image of 30 nm Pd NSs. Figure S2: Quantitative content analysis of Au and Pd in Pd@Au NSs by ICP-MS analysis. Figure S3: UV-Vis-NIR absorption spectrum of (a) Pd-PEG NSs and (b) Pd@Au-PEG NSs. Figure S4: Zeta potentials comparison of Pd@Au NSs and Pd@Au-PEG NSs. Figure S5: Hydrodynamic sizes of (a) Pd@Au NSs and (b) Pd@Au-PEG NSs incubated in the saline at day-1, -3, -5 and -7. Figure S6: The absorption spectrum of Pd@Au-PEG NSs incubated in the saline at day-1, -3, -5 and  -7. Figure S7: Enzymatic activity of Pd@Au-PEG NSs under various pH conditions. Figure S8: (a) Photothermal converting ability of Pd@Au-PEG NSs with various concentrations under the excitation of NIR-II laser (1064 nm, 0.3 W cm− 2). (b) NIR-II photothermal converting ability of Pd@Au-PEG NSs (40 ppm) under the excitation of NIR-II laser with various power density. Figure S9: TEM image of Pd@Au-PEG NSs after photothermal stability test (Scale bar = 50 nm). Figure S10: The subcellular localization of Cy5.5-labeled Pd NSs (Scale bar = 10 µm). Figure S11: In vitro PA images of Pd@Au-PEG NSs with various concentrations (0, 16, 32, 63, 125, 250 and 500 ppm) and the linear relationship between the PA signal intensity and Pd@Au-PEG NSs concentration. Fig. S12: In vitro CT images of Pd@Au-PEG NSs with various concentrations (0, 20, 40, 80, 100, 160 and 200 ppm) and the linear relationship between the CT signal intensity and Pd@Au-PEG NSs concentration. Fig. S13: Small animal living fluorescence imaging of Pd@Au-Cy5.5 NSs-injected mice at 6 h and 24 h post-injection (Red circles and arrows represent the tumor sites). Fig. S14: (a) In vitro fluorescence images of major organs obtained from Pd@Au-Cy5.5-injected mice at 24 h post-injection (H: Heart, Li: Liver, S: Spleen; Lu: Lung, K: Kidney, T: Tumor). (b) The quantitative analysis of tissue fluorescence intensity. Fig. S15:In vivo NIR-II moderate PTT images of Pd@Au-PEG NSs-injected mice. Fig. S16: (a) The size of tumors at 16th days post-treatment. (b) The weight of tumor samples at 16th days post-treatment from each treatment groups. Fig. S17: The average growth curves of 4T1 subcutaneous tumors treated by different therapeutic modalities. Fig. S18: The quantitative analysis of TUNEL fluorescence intensities in each treatment group. Fig. S19: H&amp;E staining images of major health tissues including heart, liver, spleen, lung and kidney of mice in each treatment group (Scale bar = 50 µm). Fig. S20: Hematological index measurements of Pd@Au-PEG NSs-injected mice